Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma

Shaojie Wu, Yanni Deng, Mingyao Lai, Sanfang Tu, Linbo Cai, Yuhua Li

Blood (2024) 144 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2024-200645

Published: 2024

Journal Articles

Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

Chuting Yang, Rui Huang, Danian Nie, Yiqing Li, Yuming Zhang, Honghua He, Chaoyang Song, Sanfang Tu, Yaling Zheng, Xuan Zhou, Jie Chen, Hui Zeng, Yuhua Li

Blood (2024) 144 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2024-201586

Published: 2024

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Journal Articles

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Fu Cheng Cheng, Song Jin, Junling Zhuang, Xin Zhou, Fan Zhou, Yuhua Li, Kaiyang Ding, Ting Niu, Wenming Chen, Baijun Fang, Li-Li Chen, Rong Fu, Hao Zhang, Jiaping Fu, Xiuju Wang, Sha Liu, Lin Li, Depei Wu

Blood (2024) 144 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2024-204366

Published: 2024

Journal Articles

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Blood (2024) 144 (Supplement 1): 2187.

https://doi.org/10.1182/blood-2024-206919

Published: 2024

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

Shaojie Wu, Junru Du, Jie Ma, Li Huang, Zhiqiang Peng, Yiwen Ling, Xiaofang Deng, Weijian Zhu, Hongliang Li, Hua Wang, Yuhua Li

Blood (2024) 144 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2024-200667

Published: 2024

Journal Articles

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2024-198959

Published: 2024

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Langqi Wang, Jilong Yang, Bo Jin, Bo Wang, Lijuan Zhou, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Sanfang Tu, Yuhua Li

Blood (2023) 142 (Supplement 1): 4841.

https://doi.org/10.1182/blood-2023-186439

Published: 2023

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Meifang Li, Bo Jin, Langqi Wang, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 6884.

https://doi.org/10.1182/blood-2023-186622

Published: 2023

Journal Articles

Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis

Shaojie Wu, Sanfang Tu, Zhenjun Zhou, Xinlin Sun, Anqin Wu, Lei Wang, Yuhua Li

Blood (2023) 142 (Supplement 1): 6322.

https://doi.org/10.1182/blood-2023-181471

Published: 2023

Journal Articles

Safety and Efficacy of Single Cycle Blinatumomab Plus VP Chemotherapy for High Tumor Burden Acute Lymphoblastic Leukemia in Adults

Sanfang Tu, Kecheng Wang, Chaoyang Song, Xuan Zhou, Dan Xiong, Guinian Huang, Jia Feng, Jilong Yang, Bo Jin, Bo Wang, Langqi Wang, Yaqi Zhuo, Huifang Chen, Yuhua Li

Blood (2023) 142 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2023-184746

Published: 2023

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Meifang Li, Bo Jin, Langqi Wang, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2023-186888

Published: 2023

Journal Articles

Venetoclax Combined with HMA Versus CAG Based Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis

Xiaonan Lin, Yuming Zhang, Ying Zhao, Ying Dong, Xiaotao Wang, Pengcheng Huang, Zhenqian Huang, Honghua He, Xiaoli Xu, Yaya Wang, Fang Jiang, Hui Zeng, Rui Huang, Yuhua Li

Blood (2023) 142 (Supplement 1): 2901.

https://doi.org/10.1182/blood-2023-182642

Published: 2023

Journal Articles

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

Sanfang Tu, Lijuan Zhou, Rui Huang, Yanjie He, Xuan Zhou, Jilong Yang, Yuxing Hu, Honghao Zhang, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2023-186308

Published: 2023

Journal Articles

Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2023-177568

Published: 2023

Journal Articles

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Blood (2023) 142 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2023-188961

Published: 2023

Journal Articles

A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study

Blood (2023) 142 (Supplement 1): 4951.

https://doi.org/10.1182/blood-2023-184407

Published: 2023

Journal Articles

Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Trial

Chuting Yang, Yaling Zheng, Chaoyang Song, Ming Wu, Lei Wang, Xuan Zhou, Chunyan Yue, Xiaonan Lin, Jie Chen, Hui Zeng, Rui Huang, Yuhua Li

Blood (2023) 142 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2023-174879

Published: 2023

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Zixun Yan, Dehui Zou, Yuhua Li, Xiaojian Zhu, Dongmei Ji, Wenbin Qian, Ying Lu, Chunyan Ji, Keshu Zhou, Hongmei Jing, Hua Yang, Lanfang Li, Fei Li, Kailin Xu, Ting Niu, Depei Wu, Yu Hu, Weili Zhao

Blood (2023) 142 (Supplement 1): 6928.

https://doi.org/10.1182/blood-2023-181351

Published: 2023

NARROW

Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma

Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis

Safety and Efficacy of Single Cycle Blinatumomab Plus VP Chemotherapy for High Tumor Burden Acute Lymphoblastic Leukemia in Adults

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Venetoclax Combined with HMA Versus CAG Based Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study

Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Trial

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only